T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ORKA
1051
Oruka Therapeutics
ORKA
$7.11B
| $19.7M | ﹤0.01% |
649,346
+22,540
| +4% | +$628K |
|
1052
Masco
MAS
$14.7B
| $19.7M | ﹤0.01% |
310,043
-2,317
| -0.7% | -$150K |
|
1053
Mirion Technologies
MIR
$3.79B
| $19.5M | ﹤0.01% |
834,330
| – | – |
|
|
FLY
1054
Firefly Aerospace
FLY
$4.48B
| $19.5M | ﹤0.01% |
869,939
-991,401
| -53% | -$22.9M |
|
1055
IMAX
IMAX
$2.81B
| $19.4M | ﹤0.01% |
524,316
+1,613
| +0.3% | +$56.2K |
|
1056
Vale
VALE
$61.4B
| $19.4M | ﹤0.01% |
1,485,036
-97,385
| -6% | -$1.18M |
|
1057
Aaon
AAON
$7.23B
| $19.3M | ﹤0.01% |
252,541
-27,579
| -10% | -$2.55M |
|
1058
Best Buy
BBY
$18B
| $19.2M | ﹤0.01% |
286,857
+5,227
| +2% | +$399K |
|
1059
SPS Commerce
SPSC
$2.86B
| $19M | ﹤0.01% |
213,564
-3,425
| -2% | -$318K |
|
1060
Nordson
NDSN
$17.3B
| $19M | ﹤0.01% |
79,061
-633
| -0.8% | -$149K |
|
1061
Evertec
EVTC
$1.91B
| $19M | ﹤0.01% |
652,513
+7,886
| +1% | +$234K |
|
1062
Jack Henry & Associates
JKHY
$10.8B
| $19M | ﹤0.01% |
103,949
-1,737
| -2% | -$289K |
|
1063
Matador Resources
MTDR
$6.5B
| $18.9M | ﹤0.01% |
444,268
-369,023
| -45% | -$15.5M |
|
1064
UiPath
PATH
$8.64B
| $18.8M | ﹤0.01% |
1,146,494
+809,315
| +240% | +$12.6M |
|
1065
Bright Horizons
BFAM
$3.76B
| $18.6M | ﹤0.01% |
183,323
-216,417
| -54% | -$21.8M |
|
1066
Clorox
CLX
$12.8B
| $18.5M | ﹤0.01% |
183,792
-1,822
| -1% | -$198K |
|
1067
Aecom
ACM
$7.86B
| $18.5M | ﹤0.01% |
194,092
+18,638
| +11% | +$2.19M |
|
1068
Akamai
AKAM
$18B
| $18.3M | ﹤0.01% |
209,980
-74,751
| -26% | -$6.15M |
|
1069
Asbury Automotive
ABG
$3.76B
| $18.3M | ﹤0.01% |
78,689
-8,378
| -10% | -$1.98M |
|
1070
Reinsurance Group of America
RGA
$16.1B
| $18.2M | ﹤0.01% |
89,643
+13,964
| +18% | +$2.7M |
|
1071
Bunge Global
BG
$21.5B
| $18.1M | ﹤0.01% |
203,435
+4,324
| +2% | +$399K |
|
1072
TG Therapeutics
TGTX
$7.58B
| $18.1M | ﹤0.01% |
605,945
-352,526
| -37% | -$11.5M |
|
|
GRAL
1073
GRAIL Inc
GRAL
$3.08B
| $18M | ﹤0.01% |
210,768
+179,068
| +565% | +$15.5M |
|
1074
Paymentus
PAY
$5.08B
| $18M | ﹤0.01% |
569,016
+162,845
| +40% | +$5.31M |
|
1075
International Bancshares
IBOC
$4.52B
| $17.9M | ﹤0.01% |
268,654
+219,578
| +447% | +$14.9M |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.